Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 230 participants.
Also called NCT07911124
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 230 participants
- Registry
-
NCT07911124
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07911124. Randomized; quadruple masking; primary purpose treatment. Start 2026-11 (anticipated); primary completion 2030-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ticagrelor for Inflammation and Cardiovascular Risk in Patients With Chronic Kidney Disease
- Acronym
- TACTIC-CKD
- Intervention (Drug)
- Ticagrelor: an oral, direct-acting, reversibly binding P2Y12 receptor antagonist
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Arkansas
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct07911124- Content hash
681cee249588c530b6581120c85e0718b21d6bb4a6fc03e8ed56df91d0481d22